Dr. Jeffrey Jones on Idelalisib and Ibrutinib in Patients With CLL

Jeffrey Jones, MD, discusses treatment options for patients with chronic lymphocytic leukemia (CLL) who progress on, or become intolerant of, idelalisib or ibrutinib during their treatment.

Jeffrey Jones, MD, assistant professor of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia (CLL) who progress on, or become intolerant of, idelalisib or ibrutinib during their treatment. Jones says one option is to begin salvage treatment with either idelalisib or ibrutinib after one of the two treatment options fails. Utilizing the treatment option not initially chosen has resulted in about a 50% response rate.